Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.40Par Drugs & Chemicals Ltd showcases a very strong financial profile, marked by exceptional profitability and a complete absence of debt. This debt-free status provides remarkable financial stability and insulates it from risks associated with interest payments. The company's ability to meet its short-term financial obligations is also excellent, indicating a high level of liquidity. Growth has been robust in terms of sales and overall earnings, suggesting successful business expansion. However, the company's operational efficiency presents a mixed picture; while it manages its inventory superbly, it appears to be underutilizing its fixed assets and capital to generate sales. A key point for investors is that the company does not pay dividends, retaining earnings for growth. The future outlook appears positive, supported by strong profits and a secure financial base, though a decline in operating profit growth points to potential margin pressures.
Health Score : 7.40Par Drugs & Chemicals Ltd showcases a very strong financial profile, marked by exceptional profitability and a complete absence of debt. This debt-free status provides remarkable financial stability and insulates it from risks associated with interest payments. The company's ability to meet its short-term financial obligations is also excellent, indicating a high level of liquidity. Growth has been robust in terms of sales and overall earnings, suggesting successful business expansion. However, the company's operational efficiency presents a mixed picture; while it manages its inventory superbly, it appears to be underutilizing its fixed assets and capital to generate sales. A key point for investors is that the company does not pay dividends, retaining earnings for growth. The future outlook appears positive, supported by strong profits and a secure financial base, though a decline in operating profit growth points to potential margin pressures.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
13.20
Industry Median
25.43
Small Cap Median
25.43
P/E RATIO
13.20
P/B RATIO
1.55
Industry Median
1.55
Small Cap Median
1.55
P/S RATIO
1.66
Industry Median
1.66
Small Cap Median
1.66
Others
PEG RATIO
2.44
EV/EBITDA RATIO
6.24
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹140.6 as on Sep 1, 2026.
Growth Score : 8.80The company presents a strong but somewhat contradictory growth picture. It has achieved excellent growth in revenues, assets, and bottom-line profits, which is very positive for its long-term prospects and shareholder value. However, a significant concern is the decline in operating profit. This suggests that while the company is getting bigger and selling more, the profitability of its core business operations is being squeezed, possibly due to rising costs or competitive pressures. This divergence warrants attention as it could impact future overall profitability.
Revenue Growth RateExcellent
Operating Profit Growth RatePoorEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 22.95 | 28 | 0 | 5.21 | 2.97 |
| Operating Profit Growth Rate | 0 | 12.5 | 27.78 | -13.04 | -15 |
| Earnings Per Share (EPS) Growth | -20.66 | 22.96 | 27.9 | -7.81 | -1.93 |
| Asset Growth Rate | 3.95 | 12.66 | 14.61 | 16.67 | 8.4 |
| Net Income Growth Rate | -25 | 22.22 | 27.27 | -7.14 | 0 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 13.20 | Neutral | 17.00 | 10.65 | 13.00 |
| 2 | Vaishali Pharma Ltd | 6.74 | 25.09 | Neutral | 4.00 | 0.31 | 4.00 |
| 3 | Quest Laboratories Ltd | 5.27 | 9.34 | Neutral | 18.00 | 9.16 | 15.00 |
| 4 | Sotac Pharmaceuticals Ltd | 5.27 | 17.25 | Neutral | 18.00 | 4.45 | 6.00 |
| 5 | Zenith Drugs Ltd | 4.63 | 7.41 | Neutral | 17.00 | 2.30 | 10.00 |
| 6 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 7 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.36 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Par Drugs & Chemicals Ltd is an Indian manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. The company focuses on producing a range of products used in various therapeutic areas, serving both domestic and international markets. It holds a niche position in the chemical and pharmaceutical supply chain, emphasizing quality and custom synthesis capabilities.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Par Drugs & Chemicals Ltd's P/E ratio (TTM) is 13.20, compared to the industry median of 25.43 and large cap median of 25.43.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Par Drugs & Chemicals Ltd's P/B ratio is 1.55, compared to the industry median of 1.55 and large cap median of 1.55.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Par Drugs & Chemicals Ltd's P/S ratio is 1.66, compared to the industry median of 1.66 and large cap median of 1.66.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Par Drugs & Chemicals Ltd's PEG ratio is 2.44.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Par Drugs & Chemicals Ltd's EV/EBITDA ratio is 6.24.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Par Drugs & Chemicals Ltd's ROE is 11.61%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Par Drugs & Chemicals Ltd's ROA is 13.18%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Par Drugs & Chemicals Ltd's ROCE is 17%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Par Drugs & Chemicals Ltd's operating margin is 16.35%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Par Drugs & Chemicals Ltd's net margin is 12.50%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Par Drugs & Chemicals Ltd's current ratio is 3.82.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Par Drugs & Chemicals Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Par Drugs & Chemicals Ltd's interest coverage ratio is N/A.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Par Drugs & Chemicals Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Par Drugs & Chemicals Ltd's EPS is -1.93.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹140.60. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1999
Headquarters: Ankleshwar, Gujarat
Core Offerings: Active Pharmaceutical Ingredients (APIs), Pharmaceutical Intermediates, Specialty Chemicals, Custom Synthesis
Stock Listing: NSE (PAR), BSE ({bse})
Promoter: Rajan Natvarlal Shah / Shah Family
Par Drugs & Chemicals Limited was incorporated in 1999, establishing its manufacturing facility in Ankleshwar, Gujarat. The company initially focused on pharmaceutical intermediates and gradually expanded its product portfolio to include a diverse range of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. Over the years, it has strengthened its R&D capabilities and manufacturing processes to cater to both domestic and international pharmaceutical and chemical industries.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical & Specialty Chemicals Manufacturing | 100% | N/A - consolidated results |
Active Pharmaceutical Ingredients (APIs): Manufactures key ingredients for various drug formulations, adhering to stringent quality standards for both domestic and export markets.
Pharmaceutical Intermediates: Produces chemical compounds essential in the synthesis of APIs, supporting the pharmaceutical supply chain.
Specialty Chemicals: Engaged in the production of specialized chemicals catering to diverse industrial applications beyond pharmaceuticals.
Custom Synthesis: Offers tailor-made chemical synthesis services to clients based on specific requirements and specifications.
Mr. Rajan Natvarlal Shah - Chairman & Managing Director. A seasoned entrepreneur with extensive experience in the chemical and pharmaceutical industry, he has been instrumental in the company's growth and strategic direction since its inception.
No major subsidiaries reported.
No major recent corporate actions on record.
The Par Drugs & Chemicals Ltd share price today is ₹140.60 on NSE (PAR), as of 26 Sept 2026.
As of 26 Sept 2026, Par Drugs & Chemicals Ltd share price is ₹140.60, with previous close ₹140.60. Today's range is ₹140.60 to ₹140.60. The 52-week range is ₹78.05 to ₹180.
As of today, Par Drugs & Chemicals Ltd's market cap is ₹172.94 crore (Small Cap).
Par Drugs & Chemicals Ltd's current P/E ratio is 13.20, compared to the AUTOMOBILES & AUTO PARTS MANUFACTURERS sector average of 33.50.
Par Drugs & Chemicals Ltd's current P/B ratio is 1.55.
Par Drugs & Chemicals Ltd's current dividend yield is N/A. Last dividend of ₹0.50 per share was declared on 28-May-2024.
Par Drugs & Chemicals Ltd's EPS (TTM) is ₹-1.93.
Par Drugs & Chemicals Ltd is an Indian manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. The company focuses on producing a range of products used in various therapeutic areas, serving both domestic and international markets. It holds a niche position in the chemical and pharmaceutical supply chain, emphasizing quality and custom synthesis capabilities.
Par Drugs & Chemicals Ltd is promoted by Rajan Natvarlal Shah / Shah Family, holding 73.41% as of 26 Sept 2026.
Par Drugs & Chemicals Ltd is listed on NSE (PAR) and BSE ({bse}). Its next quarterly results are expected on July/August 2024 (for Q1 FY25).
